About indaptus therapeutics inc - INDP
Indaptus Therapeutics, Inc. is a clinical biotechnology company. The firm engages in the development of a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It created patented treatment methods and associated patented compositions for attenuation and killing of non-pathogenic, Gram-negative bacteria. The company was founded by Michael James Newman on February 24, 2021 and is headquartered in New York, NY.
INDP At a Glance
Indaptus Therapeutics, Inc.
3 Columbus Circle
New York, New York 10019
| Phone | 1-646-427-2727 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -20,848,916.00 | |
| Sector | Health Technology | Employees | 5 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
INDP Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 2.008 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.287 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
INDP Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -4,169,783.20 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
INDP Liquidity
| Current Ratio | 1.512 |
| Quick Ratio | 1.512 |
| Cash Ratio | 1.381 |
INDP Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -250.454 |
| Return on Equity | -587.586 |
| Return on Total Capital | -661.536 |
| Return on Invested Capital | -587.586 |
INDP Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |